Hamzavi Dermatology

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Psoriasis4 trials
• Vitiligo2 trials
• Alopecia areata1 trial
• Atopic dermatitis (eczema)1 trial
• Hidradenitis suppurativa1 trial

Phase

• Phase 37 trials
• Phase 23 trials

Status

• Completed5 trials
• Active, not recruiting4 trials
• Recruiting1 trial

Lead sponsor

• Janssen Research & Development, LLC3 trials
• Bristol-Myers Squibb1 trial
• Eli Lilly and Company1 trial
• Incyte Corporation1 trial
• Nielsen BioSciences, Inc.1 trial
• and 3 more

Running trials

• Recruiting

  A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

  NCT07431177· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Lee Campbell

• Active, not recruiting

  A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

  NCT07244263· Phase 2· Takeda· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

  NCT06095102· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Vitiligo1 recruiting

Closed trials

• Completed

  Candin for the Treatment of Common Warts

  NCT05889845· Phase 3· Nielsen BioSciences, Inc.· Source

• Completed

  A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

  NCT05750823· Phase 2· Incyte Corporation· Source

• Completed

  Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

  NCT04036435· Phase 3· Bristol-Myers Squibb· Source

• Completed

  A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

  NCT03899259· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source